MeSH D006950 - familial combined hyperlipidemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Organon | Ezetimibe, Atorvastatin | Liptruzet |  | 2013-05-03 | $260 M | Q1/23-Q1/24 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/2
Phase 2
0%0/0
Phase 3
67%2/3
Approved: 2Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use